Summary of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings on May 17, 2018

May 17, 2018 - By Nell Hawkins

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Corporate Logo

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Total analysts of 5 have positions in Adamis Pharma (NASDAQ:ADMP) as follows: 5 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 4, 2017 according to StockzIntelligence Inc Adamis Pharma has 5 analyst reports. On Friday, March 23 the firm has “Buy” rating given by B. Riley & Co. On Monday, May 14 the firm has “Buy” rating given by Maxim Group. On Monday, May 14 the rating was maintained by FBR Capital with “Buy”. On Monday, December 4 the rating was maintained by Raymond James with “Buy”. Listed here are Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) PTs and latest ratings.

14/05/2018 Broker: FBR Capital Rating: Buy New Target: $6.2500 Maintain
14/05/2018 Broker: Maxim Group Old Rating: Buy New Rating: Buy Old Target: $5 New Target: $10 Maintain
23/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7 Initiates Coverage On
23/03/2018 Broker: B. Riley & Co Old Rating: Buy New Rating: Buy Old Target: $7.5 New Target: $6.25 Maintain
04/12/2017 Broker: Raymond James Rating: Buy New Target: $7.0 Maintain

ADMP is touching $4.16 during the last trading session, after increased 2.18%.Currently Adamis Pharmaceuticals Corporation is downtrending after 20.00% change in last May 17, 2017. ADMP has 146,478 shares volume. ADMP underperformed the S&P 500 by 31.55%.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States.The firm is worth $139.03 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease.Last it reported negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

A couple more Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were posted by: Nasdaq.com which released on May 10, 2018 “Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update”, also Seekingalpha.com on May 14, 2018 posted “Adamis Pharmaceuticals: Paging Dr. Carlo”, the next Nasdaq.com is “Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences …” on April 19, 2018. Seekingalpha.com has article titled “Adamis Keeps Us Waiting: April Update”.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.